Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Inclusion Criteria

• •Patients must have castrate refractory prostate cancer with prior docetaxel treatment which was used in the castrate refractory setting
• •Cancer Progression as defined by prostate cancer working group 3 (PCWG3) any type- prostate specific antigen only, bone only +nodal, nodal only or new lesions
• •Age 18 or older.
• •ECOG 0, 1, or 2
• •Life expectancy of greater than 2 months
• •Men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for three (3) months after study treatment discontinuation.
• •Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
• •Organ \& marrow function as defined below: Absolute neutrophil count \>1,200/mcL, Platelets \>75,000/mcL; total bilirubin = within normal institutional limits; AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal; creatinine \<2.5 X institutional upper limit of normal